Research Analysts’ Updated EPS Estimates for August, 7th (ACAD, AFH, AKCA, ALDR, AMRS, AVGO, BIIB, CRNT, CYTR, DPSGY)

Research Analysts’ updated eps estimates for Tuesday, August 7th:

Stifel Nicolaus began coverage on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD). The firm issued a hold rating and a $17.00 target price on the stock.

Atlas Financial (NASDAQ:AFH) was upgraded by analysts at Boenning Scattergood to a buy rating. The firm currently has $10.00 target price on the stock. The analysts wrote, “We are upgrading our rating for Atlas’ common stock to Outperform from Neutral. Atlas booked a good 2Q18 on the heels of a solid 1Q18, continuing to move in the right direction as management works to rebuild investor trust following the company’s significant reserve charge in 4Q17. While the risk of additional adverse reserve development remains (two good quarters following the large reserve charge does not mean the company is out of the woods yet), we believe upside potential outweighs downside risk. The stock declined 40% in March upon the news of the reserve charge and is off an additional 25% since then, partly attributed, we believe, to a financial strength rating downgrade by A.M. Best and the stock’s removal from the Russell 2000. While certainly a negative, management does not expect the A.M.””

Akcea Therapeutics (NASDAQ:AKCA) had its hold rating reissued by analysts at Stifel Nicolaus. Stifel Nicolaus currently has a $33.00 price target on the stock.

Stifel Nicolaus initiated coverage on shares of Alder Biopharmaceuticals (NASDAQ:ALDR). They issued a buy rating and a $30.00 price target on the stock.

Amyris (NASDAQ:AMRS) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $15.00 price target on the stock. The analysts wrote, “Turtle Beach reported 2Q18 revenues/EBITDA of $61M/$9.8M, better than consensus of $48M/$3.1M(E) and our $48M/$3.2M(E). The strong sales performance in 2Q (up 218%) was driven by accelerating sell-through and moderate share gain. Management again attributed the outperformance to new demand created by battle royale games such as PUBG and Fortnite. Although it remains to be seen if sell- through momentum can sustain after the coming holiday season, HEAR has already gone through a meaningful transformation with a healthier balance sheet and an expanded installed headset base, both setting up the company well for long-term investments and growth. We raise our FY18 estimates and price target to $35 (was $31). Reiterate Outperform.””

Barclays PLC began coverage on shares of Broadcom (NASDAQ:AVGO). They issued an overweight rating on the stock.

Stifel Nicolaus initiated coverage on shares of Biogen (NASDAQ:BIIB). The firm issued a buy rating and a $394.00 target price on the stock.

Ceragon Networks (NASDAQ:CRNT) had its hold rating reiterated by analysts at Oppenheimer Holdings Inc..

CytRx (NASDAQ:CYTR) had its buy rating reissued by analysts at HC Wainwright. The firm currently has a $4.50 target price on the stock. The analysts wrote, “Our price target is based on a composite valuation assessment that ascribes: (1) $105M to the future royalty streams from sales of aldoxorubicin, to which we assign a 60% probability of success and 12% discount rate; and (2) $80M to the LADR portfolio of candidates, which includes the companion diagnostic platform.””

DEUTSCHE POST A/S (OTCMKTS:DPSGY) had its buy rating reiterated by analysts at UBS Group AG.

1&1 Drillisch (ETR:DRI) had its buy rating reaffirmed by analysts at UBS Group AG.

Deutsche Telekom (FRA:DTE) had its buy rating reissued by analysts at UBS Group AG.

Etsy (NASDAQ:ETSY) had its buy rating reissued by analysts at KeyCorp. They currently have a $51.00 target price on the stock.

Fate Therapeutics (NASDAQ:FATE) had its hold rating reiterated by analysts at HC Wainwright. They currently have a $12.00 target price on the stock. The analysts wrote, “Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x.””

Illumina (NASDAQ:ILMN) was upgraded by analysts at Morgan Stanley from an underweight rating to an equal weight rating.

MasTec (NYSE:MTZ) was upgraded by analysts at Robert W. Baird from a neutral rating to an outperform rating.

Microvision (NASDAQ:MVIS) had its buy rating reiterated by analysts at HC Wainwright. They currently have a $3.50 target price on the stock.

Stifel Nicolaus assumed coverage on shares of Neurocrine Biosciences (NASDAQ:NBIX). They issued a buy rating and a $137.00 price target on the stock.

Telefonica Deutschland (ETR:O2D) had its buy rating reissued by analysts at UBS Group AG.

Corporate Office Properties Trust (NYSE:OFC) was upgraded by analysts at Bank of America Corp from a neutral rating to a buy rating. They currently have $34.00 target price on the stock.

OneMain (NYSE:OMF) was upgraded by analysts at Zacks Investment Research from a hold rating to a buy rating. They currently have $40.00 price target on the stock. According to Zacks, “OneMain Holdings Inc. is a consumer financial services holding company. The Company’s operating segments consists of Consumer and Insurance, Acquisitions and Servicing and Real Estate. OneMain Holdings Inc., formerly known as Springleaf Holdings, Inc. is based in Evansville, United States. “

Pennsylvania R.E.I.T. (NYSE:PEI) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “PENNSYLVANIA R.E. INVEST. TR. is a real estate investment trust, engaged in acquiring and holding for investment interests in real estate. “

Aratana Therapeutics (NASDAQ:PETX) was upgraded by analysts at Zacks Investment Research from a sell rating to a hold rating. According to Zacks, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas. “

SeaWorld Entertainment (NYSE:SEAS) was upgraded by analysts at Macquarie from an underperform rating to a hold rating.

Synergy Pharmaceuticals (NASDAQ:SGYP) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $7.00 price target on the stock.

Vericel (NASDAQ:VCEL) had its buy rating reaffirmed by analysts at BTIG Research. BTIG Research currently has a $17.00 price target on the stock. The analysts wrote, “$17 PT Heading into earnings, we viewed MACI’s ~23% Y/Y adjusted comp as achievable as the combo of increasing biopsy growth in YE17, rep additions, and low market penetration suggested another beatable Q. Viewed independent of the guidance raise, MACI’s 2Q18 result was in line with our Street-high expectations ($14.1M vs. BTIG’s $14.0M est.) but above Consensus ($13.7M) and while not bad, it may not excite investors looking for continued acceleration. That said, we do expect shares to be up tomorrow as guidance was raised ~9% (at the midpoint) to $80M – $83M (from $73M – $78M) as mgmt. sees strengthening momentum in 2H18 within MACI from biopsy strength, faster conversion times, new rep contributions, and continued marketing.””

Vodafone Group (NASDAQ:VOD) had its buy rating reaffirmed by analysts at UBS Group AG.

Viewray (NASDAQ:VRAY) had its buy rating reiterated by analysts at BTIG Research. They currently have a $14.00 price target on the stock. The analysts wrote, “PT to $14 from $10 VRAY preannounced 2Q rev and reported gross orders of $34.6M Friday coming in in line with consensus. Shares were probably pressured by GMs of ~0% due to one-time issues and expected cash use for the year being increased $10M. We continue to expect VRAY to require additional funding by 1H19. We like the new mgmt team’s track record both as operators and sellers of companies and expect an improvement in commercial execution. That said we felt the stock had overrun a bit to near $13 and would have moved to Neutral but with shares pulling back now still see them compelling. We are raising our out year PT to $14. While we still see VRAY as compelling we have learned quite a bit about potential new competition in MagnetTx (Private), whom we recently visited in Edmonton.””

Stifel Nicolaus started coverage on shares of Williams Companies (NYSE:WMB). They issued a buy rating and a $35.00 price target on the stock.

Xencor (NASDAQ:XNCR) had its overweight rating reiterated by analysts at Piper Jaffray Companies.

Zillow Group Inc Class A (NASDAQ:ZG) had its hold rating reissued by analysts at Jefferies Financial Group Inc. Jefferies Financial Group Inc currently has a $52.00 price target on the stock.

Receive News & Ratings for ACADIA Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ACADIA Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply